Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vincent Tubiolo

Allergy Santa Barbara, CA Medical Doctor

NPI 1083778864 CMS profile 139557

2320 Bath St Ste 303, Santa Barbara, CA 93105

Open in the dashboard

General payments

$10,183

399 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vincent Tubiolo of Santa Barbara, CA is reported in the CMS Open Payments database as having received $10,183 across 399 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,664 85
2024 General $1,893 67
2023 General $1,425 62
2022 General $1,469 60
2021 General $1,992 51
2020 General $357 18
2019 General $1,383 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vincent Tubiolo
  • Allergy median
  • Middle half of Allergy
  • National median

In program year 2025, general payments to Vincent Tubiolo were reported at $1,664. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.

Show as a table
Year Vincent Tubiolo Allergy median Middle half National median
2019 $1,383 $506 $151–$1,337 $163
2020 $357 $409 $108–$1,162 $114
2021 $1,992 $549 $125–$1,485 $132
2022 $1,469 $666 $161–$1,594 $149
2023 $1,425 $780 $186–$1,916 $160
2024 $1,893 $1,031 $271–$2,196 $164
2025 $1,664 $1,143 $226–$2,504 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $2,299 127 payments
  2. AstraZeneca Pharmaceuticals LP $1,221 41 payments
  3. Octapharma USA, Inc. $960 9 payments
  4. Regeneron Healthcare Solutions, Inc. $957 39 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $788 35 payments
  6. Genzyme Corporation $666 24 payments
  7. Novartis Pharmaceuticals Corporation $517 23 payments
  8. CSL Behring $298 12 payments
  9. Pharming Healthcare, Inc. $269 9 payments
  10. ALK-Abello, Inc $213 7 payments
  11. Other $1,997 73 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,236 393 payments
  2. Honoraria $750 1 payment
  3. Debt forgiveness $136 1 payment
  4. Consulting Fee $55 3 payments
  5. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. NUCALA $1,141 58 payments
  2. TRELEGY ELLIPTA $950 60 payments
  3. CUTAQUIG $938 8 payments
  4. DUPIXENT Inflammation And Immunology $774 28 payments
  5. DUPIXENT Immunology $754 32 payments
  6. TEZSPIRE $505 14 payments
  7. CUVITRU $418 18 payments
  8. TAKHZYRO $349 17 payments
  9. FASENRA $333 8 payments
  10. Hizentra $281 11 payments
  11. Other $4,360 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

1,515

Median for Allergy/ Immunology: 449

Drug cost

$1,218,075

Median for Allergy/ Immunology: $169,700

Branded share of claims

45.2%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 25 $288,714
Dupixent Syringe Dupilumab Brand 63 $253,243
Xolair Omalizumab Brand 67 $206,983
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 117 $105,402
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 20 $102,252
Tezspire Tezepelumab-Ekko Brand 18 $76,785
Dupixent Pen Dupilumab Brand 16 $59,711
Spiriva Respimat Tiotropium Bromide Brand 43 $26,843
Breo Ellipta Fluticasone/Vilanterol Brand 36 $24,158
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 18 $15,751

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$115,124

Medicare's payments for the services billed

Medicare patients

397

Average age 74

Services billed

8,318

249 women, 148 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 55%
Depression 20%
Osteoporosis 20%
Ischemic heart disease 17%
Chronic kidney disease 17%
COPD 15%
Diabetes 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $247
  • Regeneron Healthcare Solutions, Inc. $246
$493 79 —
NUCALA
  • GlaxoSmithKline, LLC. $225
$225 — —
XOLAIR
  • Genentech USA, Inc. $125
  • Novartis Pharmaceuticals Corporation $93
$217 67 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $153
$153 117 —
FASENRA
  • AstraZeneca Pharmaceuticals LP $142
$142 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

399 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record